Propellent gases and their use in pharmaceutical preparations

Abstract

Pharmaceutical preparations for producing powder aerosols using as the propellant gas TG 227.

1 . Propellent gases characterised in that they contain TG 227, optionally in admixture with one of more propellent gases from the group comprising TG 11, TG 12, TG 114, propane, butane, pentane and DME.  
     
     
         2 . Propellent gases according to  claim 1 , characterised in that they additionally contain at least one surface-active substance.  
     
     
         3 . Propellent gases according to  claim 2 , characterised in that the surface-active substance is a phospholipid, a sorbitan ester with a higher saturated or unsaturated fatty acid or a polyethoxysorbitan ester of a higher, preferably unsaturated fatty acid.  
     
     
         4 . Propellent gases according to  claim 2 , characterised in that the surface-active substance is a lecithin, a polyethoxyethylenesorbitan oleate or sorbitan trioleate.  
     
     
         5 . Pharmaceutical preparations for producing powder aerosols based on propellent gases according to  claim 1 ,  2 ,  3  or  4 , characterised in that they contain as active substance a betamimetic, an anticholinergic, a steroid, an antiallergic or a PAF-antagonist or a combination of such compounds.  
     
     
         6 . Pharmaceutical preparations according to  claim 5 , characterised in that the betamimetic used is: 
 Bambuterol    Bitolterol    Carbuterol    Clenbuterol    Fenoterol    Hexoprenalin    Ibuterol    Pirbuterol    Procaterol    Reproterol    Salbutamol    Salmeterol    Sulfonterol    Terbutalin    Tulobuterol    1-(2-fluoro-4-hydroxyphenyl)-2-[4-(1-benzimidazolyl)-2-methyl-2-butylamino]ethanol    erythro-5′-hydroxy-8′-(1-hydroxy-2-isopropylaminobutyl)-2H-1,4-benzoxazin-3-(4H)-one    1-(4-amino-3-chloro-5-trifluoromethylphenyl)-2-tert.-butylamino)ethanol    1-(4-ethoxycarbonylamino-3-cyano-5-fluorophenyl)-2-(tert.-butylamino)ethanol    the anticholinergic used is: 
 Ipratropium bromide  
 Oxitropium bromide  
 Trospium chloride  
 Benzilic acid-N-β-fluoroethylnortropine ester methobromide  
   the steroid used is: 
 Budesonide  
 Beclomethasone (or the  17 ,  21 -dipropionate thereof)  
 Dexamethason-21-isonicotinate  
 Flunisolide  
   The antiallergic agent is: 
 Disodium cromoglycate  
 Nedocromil  
   The PAF-antagonist is: 
 WEB 2086  
 WEB 2170  
 WEB 2347.  
   
     
     
         7 . Pharmaceutical preparations according to  claim 5 , characterised in that the combination of the active substances comprises one of the betamimetics specified in  claim 6  and one of the anticholinergics specified in  claim 6 .  
     
     
         8 . Pharmaceutical preparation according to  claim 5 , characterised in that the combination of the active substances comprises one of the betamimetics specified in  claim 6  and disodium chromoglycate.  
     
     
         9 . Pharmaceutical preparation according to  claim 5 ,. characterised in that the combination of the active substances contains one of the betamimetics specified in  claim 6  and one of the PAF-antagonists specified in  claim 6 .  
     
     
         10 . Pharmaceutical preparation according to  claim 5 , characterised in that the combination of the active substances comprises disodium chromoglycate and one of the PAF-antagonists specified in  claim 6 .  
     
     
         11 . Process for preparing pharmaceutical preparations according to  claims 5  to  10 , characterised in that pharmaceutically active substances micronised by conventional methods are suspended in a liquefied propellent gas mixture according to  claim 1 ,  2 ,  3  or  4 , optionally with the addition of surface-active substances.